BioCryst & Celgene Suffer English Funding Setback For Rare Disease Drugs

NICE’s Recommendations Are Out For Consultation until 28 July

 
• By Neena Brizmohun
Financial management
NICE says that two new products are not cost-effective enough • Source: Alamy

More from United Kingdom

More from Europe